Literature DB >> 23850274

Dosimetric comparison of optimization methods for multichannel intracavitary brachytherapy for superficial vaginal tumors.

Carminia Lapuz1, Claire Dempsey, Anne Capp, Peter C O'Brien.   

Abstract

PURPOSE: Multichannel vaginal applicators allow treatment of a more conformal volume compared with a single, central vaginal channel. There are several optimization methods available for use with multichannel applicators, but no previous comparison of these has been performed in the treatment of superficial vaginal tumors. Accordingly, a feasibility study was completed to compare inverse planning by simulated annealing (IPSA), dose point optimization (DPO), and graphical optimization for high-dose-rate brachytherapy using a multichannel, intracavitary vaginal cylinder. METHODS AND MATERIALS: This comparative study used CT data sets from five patients with superficial vaginal recurrences of endometrial cancer treated with multichannel intracavitary high-dose-rate brachytherapy. Treatment plans were generated using DPO, graphical optimization, surface optimization with IPSA (surf IPSA), and two plans using volume optimization with IPSA. The plans were evaluated for target coverage, conformal index, dose homogeneity index, and dose to organs at risk.
RESULTS: Best target coverage was achieved by volume optimization with IPSA 2 and surf IPSA with mean V100 values of 93.89% and 91.87%, respectively. Doses for the most exposed 2-cm(3) of the bladder (bladder D2cc) was within tolerance for all optimization methods. Rectal D2cc was above tolerance for one DPO plan. All volume optimization with IPSA plans resulted in higher vaginal mucosa doses for all patients. Greatest homogeneity within the target volume was seen with surf IPSA and DPO. Highest conformal indices were seen with surf IPSA and graphical optimization.
CONCLUSIONS: Optimization with surf IPSA was user friendly for the generation of treatment plans and achieved good target coverage, conformity, and homogeneity with acceptable doses to organs at risk.
Copyright © 2013 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brachytherapy; IPSA; Intracavitary; Optimization; Vagina

Mesh:

Year:  2013        PMID: 23850274     DOI: 10.1016/j.brachy.2013.04.009

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  5 in total

1.  Dosimetric comparison of manual forward planning with uniform dwell times versus volume-based inverse planning in interstitial brachytherapy of cervical malignancies.

Authors:  Siddanna R Palled; Nikhila K Radhakrishna; Senthil Manikantan; Hashmath Khanum; Bindu K Venugopal; Lokesh Vishwanath
Journal:  Rep Pract Oncol Radiother       Date:  2020-09-11

2.  Single versus multichannel applicator in high-dose-rate vaginal brachytherapy optimized by inverse treatment planning.

Authors:  Yasir A Bahadur; Camelia Constantinescu; Ashraf H Hassouna; Maha M Eltaher; Noor M Ghassal; Nesreen A Awad
Journal:  J Contemp Brachytherapy       Date:  2014-12-31

3.  Comparison of graphical optimization or IPSA for improving brachytheraphy plans associated with inadequate target coverage for cervical cancer.

Authors:  ZhiJie Liu; HuanQing Liang; Xiao Wang; HaiMing Yang; Ye Deng; TingJun Luo; ChaoFeng Yang; Min Lu; QingGuo Fu; XiaoDong Zhu
Journal:  Sci Rep       Date:  2017-11-27       Impact factor: 4.379

4.  Dose optimization in gynecological 3D image based interstitial brachytherapy using martinez universal perineal interstitial template (MUPIT) -an institutional experience.

Authors:  Pramod Kumar Sharma; Praveen Kumar Sharma; Jamema V Swamidas; Umesh Mahantshetty; D D Deshpande; Jayanand Manjhi; D V Rai
Journal:  J Med Phys       Date:  2014-07

5.  Bladder and rectum dose estimations on digitized radiographs for vaginal brachytherapy after hysterectomy.

Authors:  Winson Zhang; Sundershan K Bhatia; Wenqing Sun; Joseph M Modrick; Yusung Kim
Journal:  J Appl Clin Med Phys       Date:  2014-11-08       Impact factor: 2.102

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.